

1 **Micro-encapsulation extends mycelial viability of *Streptomyces***  
2 ***lividans* 66 and increases enzyme production**

3

4 Boris Zacchetti\*, Agathoklis Andrianos\*, Dino van Dissel\*, Evelien de Ruiter, Gilles P. van  
5 Wezel and Dennis Claessen<sup>#</sup>

6

7 Microbial Biotechnology, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333  
8 BE Leiden, The Netherlands

9

10 \* These authors contributed equally to this work

11

12 <sup>#</sup> Author for correspondence. Tel: +31 715275052; email: D.Claessen@biology.leidenuniv.nl.

13

14 **Contacts:**

15 Boris Zacchetti: b.zacchetti@biology.leidenuniv.nl

16 Agathoklis Andrianos: agathoklis.andrianos@gmail.com

17 Dino van Dissel: m.d.van.dissel@biology.leidenuniv.nl

18 Evelien de Ruiter: emderuiter@gmail.com

19 Gilles P. van Wezel: g.wezel@biology.leidenuniv.nl

20 Dennis Claessen: D.Claessen@biology.leidenuniv.nl

21

22

23

24

25

26

27

28 **Abstract**

29

30 **Background**

31 Filamentous bacteria of the genus *Streptomyces* produce a large arsenal of industrially  
32 relevant antibiotics and enzymes. The industrial production of these molecules occurs in  
33 large fermenters, where many streptomycetes form dense mycelial networks called pellets.  
34 Pellets are characterized by slow growth and inefficient nutrient transfer and therefore  
35 regarded as undesirable from the perspective of productivity. Although non-pelleting strains  
36 have increased growth rates, their morphology also leads to a dramatic increase in the  
37 viscosity of the culture broth, which negatively impacts the process dynamics.

38

39 **Results**

40 Here, we applied immobilization of *Streptomyces lividans* 66 using alginate as semi-solid  
41 matrix. This alginate-mediated micro-encapsulation increased the production of the  
42 extracellular enzyme tyrosinase more than three-fold. The increased production was  
43 accompanied by extended viability of the mycelium and a dramatic reduction in the release of  
44 intracellular proteins into the culture broth.

45

46 **Conclusions**

47 Our data demonstrate the utility of microencapsulation as a powerful technique to achieve  
48 higher yields and lower downstream-processing costs of streptomycetes.

49

50

51 **Keywords**

52 Streptomyces, microencapsulation, enzyme production

53

54

## 55 **Background**

56 Filamentous organisms are widely used in the field of industrial biotechnology. Of particular  
57 relevance are the streptomycetes, multicellular bacteria that produce a vast array of useful  
58 metabolites, including over half of the clinically relevant antibiotics, various antitumor agents,  
59 immunosuppressants, anthelmintics, antifungals, herbicides and insecticides [1, 2]. In  
60 addition, streptomycetes produce and secrete a wealth of extracellular hydrolases, which  
61 they employ to degrade the big majority of natural occurring polymers [3]. Streptomycetes  
62 grow as filaments (hyphae) that occasionally branch and establish extended cellular  
63 networks called mycelia. Growth under industrial settings is characterized by the formation of  
64 dense mycelial networks called pellets [4, 5], a phenomenon posing significant drawbacks in  
65 terms of industrial applicability. More specifically, pellets only actively grow at the periphery,  
66 which limits productivity [6, 7]. Recent work has indicated that it is possible to circumvent  
67 pellet formation in *Streptomyces lividans* by interfering with the biosynthesis of extracellular  
68 glycans produced by the *csIA-glxA* and *matAB* loci [6, 8]. These glycans mediate the  
69 adherence of hyphae, hence leading to the formation of dense clumps and pellets [4].  
70 Deletion mutants of these genes do not form pellets and grow in a dispersed manner. This  
71 increases growth and enzyme production rates [6], but comes with the offset of a higher  
72 viscosity of the culture broth (our unpublished data). To further complicate matters, pelleted  
73 growth appears to be essential at least for the production of some antibiotics [9-11]. All in all,  
74 the mycelial mode-of-growth of streptomycetes results in production processes that are  
75 characterized by a complex rheology. This translates into suboptimal mass-transfer  
76 properties, heat transfer problems, mechanical and oxidative stress [5, 10, 12].

77 An attractive alternative to classical fermentations is offered by micro-encapsulation, via the  
78 immobilization of cells in a semi-solid scaffold, often sodium alginate [13]. The behavior of a  
79 number of micro-organisms has been characterized in this immobilized state, which was  
80 found to bear several advantages. In comparison to free-living cells, immobilized cells are  
81 better protected from harsh environmental conditions [14-16] and enhanced productivity has

82 been reported [17] [18]. Additionally, immobilized cells are readily recycled or filtered, which  
83 reduces the yield loss associated with the accumulation of biomass and facilitates  
84 downstream processing [19]. In this study, we report that micro-encapsulation of the  
85 industrial workhorse *Streptomyces lividans* enhances heterologous production and purity of  
86 the extracellular enzyme tyrosinase. Our data indicate that microencapsulation provides  
87 protection against shear stress, thereby maintaining mycelial viability and integrity. This in  
88 turn stimulates production and reduces contaminations with proteins released by cell lysis.

89

## 90 **Results**

### 91 **Growth of streptomycetes in calcium-alginate microcapsules extends the viability of** 92 **the mycelium**

93 To study the effect of microencapsulation on the growth of streptomycetes, spores of *S.*  
94 *lividans*, *S. coelicolor*, *S. venezuelae* and *S. griseus* were immobilized in alginate  
95 microcapsules (see Materials and Methods). Following the immobilization step, the  
96 encapsulated spores were grown in liquid YEME or NMMP<sub>mod</sub>. After 48 h, abundant mycelial  
97 growth was detected for all strains in both media (Fig. 1 and Fig. S1). In YEME medium, the  
98 encapsulated mycelium of all strains formed highly compact mycelial clumps, while portions  
99 of the mycelium that had started to grow out of the microcapsules adopted a more relaxed  
100 morphology, whereby individual hyphae could be discerned (Fig. S1). In NMMP<sub>mod</sub> medium,  
101 the encapsulated mycelium formed less compact clumps (Fig. 1). The mycelium of all strains  
102 started to grow outside of the microcapsules after 48 h of growth, and became visible as  
103 ‘spikes’ protruding from their edges. With the exception of *S. coelicolor*, non-encapsulated  
104 mycelium was found in all strains in the liquid during the late stages of growth (Fig. 1 and Fig  
105 S2). This phenomenon was particularly evident in *S. griseus* and *S. venezuelae* at 48 h of  
106 growth, while it became apparent in *S. lividans* at 96 h of growth (Fig. S2).

107 The relaxed morphology of the encapsulated mycelium in NMMP<sub>mod</sub> compared to YEME  
108 medium, which we anticipated to be beneficial for enzyme production, was a reason to  
109 further only use NMMP<sub>mod</sub> medium. We also focused on *S. lividans*, given the prominent role  
110 of this strain for the industrial production of enzymes. To analyze how encapsulation affects  
111 mycelial viability, we performed a LIVE/DEAD analysis on the encapsulated and free-living  
112 mycelium (Fig. 2). Interestingly, a major fraction of the mycelium present in and associated  
113 with the microcapsules after 48 and 72 h of growth was viable, as derived from the  
114 pronounced staining with Syto-9. In contrast, the presence of damaged mycelium, indicated  
115 by the red PI stain, occurred significantly earlier in the free-growing mycelium, either  
116 cultivated in the presence or absence of a metal coil (used to counteract aggregation and  
117 induce fragmentation by shear). When free-growing mycelium of *S. lividans* was cultivated in

118 the absence of a metal coil in the culture flask, we noticed that the occurrence of damaged  
119 mycelium was evident after 48 h of growth, and apparently delayed in comparison to the  
120 mycelium suffering from coil-induced shear.

121

## 122 **Microencapsulation increases the heterologous production of tyrosinase**

123 To test the effect of microencapsulation on heterologous enzyme production, we introduced  
124 plasmid pIJ703 into *S. lividans* 66 [20]. This plasmid contains the *melC2* gene of  
125 *Streptomyces antibioticus*, encoding an extracellular tyrosinase that is secreted via the twin  
126 arginine translocation pathway [21]. Transformants were selected based on their ability to  
127 form the pigmented compound melanin; one of these, hereinafter called *S. lividans* pIJ703,  
128 was selected for further analysis.

129 *S. lividans* pIJ703 was encapsulated, after which the tyrosinase production was assayed and  
130 compared to the non-encapsulated controls (Fig. 3). Significantly enhanced activity was  
131 detected in the supernatant when *S. lividans* pIJ703 was grown in microcapsules, with a  
132 more than three-fold increase in comparison to the non-encapsulated strain. The highest  
133 tyrosinase activity in the supernatants of the encapsulated strain peaked after 48 h of growth,  
134 followed by a slow and gradual decrease. However, significant tyrosinase activity was still  
135 detectable at 72 h of growth. In the non-encapsulated state, the tyrosinase activity peaked at  
136 approximately 34 h of growth, after which a rapid decline was detected. After 50 h, tyrosinase  
137 activity was barely detectable. Given that the growth rate of the encapsulated mycelium  
138 could not be assessed, we measured glucose consumption over time (Fig. S3). The  
139 consumption of glucose did not show significant differences between the three culture types,  
140 suggesting that the mycelia grew at comparable rates.

141 We also qualitatively analyzed the extracellular proteins present in the culture supernatants  
142 (Fig. 4A). An SDS-PAGE analysis indicated that the supernatant of the encapsulated strain  
143 contained an abundant protein with an apparent molecular weight equal to that of tyrosinase  
144 (~ 30 kDa) after 48 h of growth, corresponding to the time point where most tyrosinase  
145 activity was detected. Conversely, the protein profiles in the supernatants of the non-

146 encapsulated control cultures were more complex and showed a large number of proteins  
147 (Fig. 4A, Fig. S4). Western analysis was used to verify that the dominant protein in the  
148 supernatant of the encapsulated strain was in fact tyrosinase (Fig. 4B). Consistent with the  
149 measured activities in the supernatant, only small amounts of tyrosinase were detected in the  
150 non-encapsulated strains. Taken together, these data demonstrate that encapsulation  
151 enhances the production of heterologously expressed tyrosinase.

152

## 153 **Discussion**

154 Streptomyces are proficient producers of enzymes and antibiotics. For industrial production  
155 processes, these organisms are usually grown as liquid-grown cultures in large scale  
156 fermenters. The growth of streptomyces under these conditions is marked by the formation  
157 of mycelial particles that consist of interconnected hyphae [4, 22]. Industrial fermenters are  
158 typically stirred at high speeds to provide homogeneous mixing but also to ensure that  
159 sufficient oxygen and nutrients are available to the growing biomass. This vigorous mixing  
160 comes at the cost of severe shear stress, which can cause fragmentation and lysis of the  
161 mycelium [23-25]. The concomitant release of intracellular contents into the culture broth  
162 thereby complicates product purification [26].

163 We here present the utility of microencapsulation as a valuable alternative approach  
164 circumventing some of the negative aspects of classical fermentations. Microencapsulation  
165 physically separates a large fraction of the mycelium from the liquid environment, with the  
166 exception of the small mycelial fragments that grow out of the capsules at late time points.  
167 While the calcium-alginate is permeable to small molecules [27], the encapsulated mycelium  
168 is protected from extrinsic mechanical stress. Our experiments demonstrate that the viability  
169 of the mycelium is prolonged inside the microcapsules, which is in agreement with earlier  
170 observations in *S. coelicolor* [18]. We conclude that this effect is obtained by reducing the  
171 degree of shear stress encountered by the mycelium. The earlier occurrence of dead  
172 mycelium in non-encapsulated cultures performed with metal coils as compared to those

173 without is also indicative of this fact. Besides extending viability, microencapsulation  
174 dramatically increased the production and purity of heterologously produced tyrosinase. The  
175 higher production was not only evident from the amount of this protein in the supernatant, but  
176 also from measurement of its specific activity throughout growth. More specifically, the  
177 amount of active tyrosinase was more than three-fold increased when the mycelium was  
178 grown inside the microcapsules.

179 Shear-induced cell lysis can be a major cause for the dissipation of substrate in  
180 streptomycetes [24]. This, accompanied by the observation that the trend in carbon  
181 consumption was similar under all conditions, suggests that the encapsulated mycelium  
182 invests more energy in production rather than in other processes, such as those related to  
183 cell repair and maintenance. The higher purity of the extracellular tyrosinase not only  
184 supports that micro-encapsulation reduces cell lysis, but also poses another major benefit:  
185 the decreased number of contaminants facilitates product purification and reduces  
186 downstream processing costs. Reduced lysis may also prevent the release of intracellular  
187 proteases in the culture broth, some of which may lead to the degradation of the desired  
188 product. Although we did not analyze this in detail, this aspect may have also contributed to  
189 the overall increase of active tyrosinase in the culture broth of the encapsulated *S. lividans*  
190 pIJ703. Also, this phenomenon might also explain the decrease in tyrosinase activity in all  
191 cultures concomitant with the appearance of abundant dead mycelium.

192

## 193 **Conclusions**

194 Our work demonstrates that micro-encapsulation of streptomycetes extends mycelial viability  
195 and enhances the production and purity of enzymes. One issue to overcome is the need to  
196 scale up to allow larger scale production with encapsulated strains. Considering this, we  
197 anticipate that our approach might be particularly suitable for the production of high-value  
198 natural products and enzymes by streptomycetes and possibly other filamentous organisms.

199



## 200 **Methods**

### 201 **Strains and culture conditions**

202 *Streptomyces coelicolor* A3(2) M145 [28], *Streptomyces lividans* 66 [20] and *Streptomyces*  
203 *venezuelae* diversa were obtained from the John Innes Centre strain collection, and  
204 *Streptomyces griseus* DSM40236 from the Deutsche Sammlung von Mikroorganismen und  
205 Zellkulturen (DSMZ). MS agar plates [29] were used to prepare spore suspensions of  
206 *Streptomyces* strains and to determine colony forming units (CFU) for the spore stocks. For  
207 liquid-grown cultures, YEME medium [29] or a modified NMMP medium (NMMP<sub>mod</sub>) were  
208 used. The buffer system of NMMP<sub>mod</sub> was optimized to avoid the detrimental effect of  
209 phosphates on the integrity of the alginate microcapsules [30]. For the preparation of 1 liter  
210 NMMP<sub>mod</sub> medium, 100 ml 0.25 M TES buffer (pH 7.2), 10 ml 0.1M Na-K buffer (pH 6.8), 25  
211 ml 20% glucose and 65 ml milliQ water were added to 800 ml NMMP basis [29]. For  
212 experiments using strains containing the tyrosinase-expressing plasmid pIJ703 [21], 10  $\mu$ M  
213 CuSO<sub>4</sub> were added to the growth medium. All cultures were grown in a total volume of 100  
214 ml of liquid medium contained in 250 ml Erlenmeyer flasks. Cultures were grown in an orbital  
215 shaker set at 30° C and 160 rpm. Unless differently stated, all experiments were performed  
216 in duplicate. For micro-encapsulation experiments, on average 75 viable spores were  
217 incorporated into every capsule with an average diameter of 415  $\mu$ m. To this end, spores  
218 were suspended in sterile liquid sodium alginate and thoroughly mixed before the preparation  
219 of microcapsules. A total of 5 ml of alginate microcapsules was used to inoculate 100 ml of  
220 medium (see *below*). We calculated the equivalent number of spores, which we used to  
221 inoculate all other cultures and which corresponded to 10<sup>5</sup> spores per ml of medium.

222

### 223 **Microscopy**

224 A Leica MZ12 stereo microscope was used for the visualization of microcapsules and  
225 encapsulated mycelium. For the visualization of live and dead mycelium, samples were  
226 stained with Syto-9 and propidium iodide (PI) (Invitrogen). To this end, pellets and

227 microcapsules were briefly sedimented via centrifugation (10 min at 2000 rpm at room  
228 temperature) and resuspended in PBS, to which Syto-9 and PI were added to a final  
229 concentration of 5  $\mu$ M and 15  $\mu$ M respectively. After mixing and incubating for 10 minutes in  
230 the dark at 30°C, samples were analyzed using a Zeiss LSM 5 EXCITER confocal  
231 microscope. Stained samples were excited at 488 and 543 nm for Syto-9 and PI,  
232 respectively. The fluorescence emission of Syto-9 was monitored in the region between 505-  
233 545 nm, while a long-pass filter of 560 nm was used to detect PI [31]. The pictures shown in  
234 Fig. 2 represent Z-stacks of at least 15 layers in the specimen with a slice thickness of 7  $\mu$ m  
235 for microcapsules and 4  $\mu$ m for pellets.

236

### 237 **Encapsulation of *Streptomyces* spores in calcium alginate**

238 Sodium alginate (Sigma-Aldrich, CAS:9005-38-3) was dissolved under constant stirring for 1  
239 hour in milliQ water to obtain a 2% solution. To remove undissolved micro-particles and other  
240 contaminants, the obtained solution was passed through two different filters. The first filter  
241 had a pore size of 1.2  $\mu$ m (GE Healthcare, CatNo:1822-047) and was used in a vacuum  
242 filtration apparatus (PALL Magnetic Filter Funnel). The filtrate was then filter-sterilized using  
243 a syringe filter with a pore size of 0.22  $\mu$ m (Sarstedt). For the production of calcium-alginate  
244 microcapsules, a home-made device was used similar to that described in [32]. This  
245 apparatus is based on a coaxial gas-flow extrusion principle, with sterile air as the used gas.  
246 The air flow was regulated via a controller (Kytola, Model E) and was set at 3 liters per  
247 minute, thus yielding alginate particles with an average diameter of 415  $\mu$ m ( $\pm$  12.3  $\mu$ m;  
248 based on analyzing 150 particles). A constant alginate flow was obtained by using a syringe  
249 pump (Fisher-Scientific) set at 30 ml/hour. The microcapsules were produced by dispersing  
250 the extruded alginate using a home-made nozzle that allowed co-axial laminar flow. While  
251 the alginate constitutes the inner sheath, air is flown in a co-axial fashion and determines the  
252 rate of formation of the alginate drops. This allowed control over the volume of the falling  
253 droplets, which were collected into a gently stirred 200 mM CaCl<sub>2</sub> solution. The cross-links  
254 formed through sodium/calcium ion exchange almost instantly transformed the liquid drops

255 into gel-like microcapsules. The alginate microcapsules were left to harden in the stirring 200  
256 mM CaCl<sub>2</sub> solution for 5 minutes. The obtained suspension of calcium-alginate  
257 microcapsules was then filtered using a vacuum filtration apparatus (PALL, GE Healthcare  
258 filters as above), after which the microcapsules were washed three times with 500 ml sterile  
259 demi-water.

260

#### 261 **Glucose measurement assay**

262 Glucose concentrations were determined using a commercial kit (Megazyme, HK/G6P-DH),  
263 according to the instructions of the manufacturer.

264

#### 265 **Tyrosinase activity assay**

266 The specific activity of tyrosinase produced by *S. lividans* harboring pIJ703 was determined  
267 by following the conversion of L-3,4-dihydroxyphenylalanine spectrophotometrically at a  
268 wavelength of 475 nm, as described earlier [33].

269

#### 270 **SDS-PAGE and Western blot analyses**

271 Supernatants of liquid-grown cultures were harvested after 48 h of growth. The culture  
272 samples were first centrifuged for 10 min at 5000 rpm and 4° C, after which the supernatants  
273 were filtered through 0.22 µm syringe filters (Sarstedt), to remove any possible contaminants  
274 (e.g whole cells, spores). Extracellular proteins were concentrated via acetone precipitation.  
275 Briefly, 1.2 ml of cold acetone (-20°C) were added to 300 µl of supernatant sample. Following  
276 thorough mixing, the sample was kept at -20°C for 1 hour and subsequently centrifuged at  
277 13,000 rpm for 10 min at 0°C. Subsequently, the liquid was removed without disturbing the  
278 protein pellet, after which 500 µl of cold acetone were added. After a second centrifugation  
279 step, the acetone was removed and the pellet was dried at 37 °C for 10 min. The obtained  
280 protein pellets were dissolved in 30 µl of 10 mM Tris-HCl buffer (pH 8.0). A Bradford analysis  
281 was used to determine the protein concentrations in the obtained samples, and 2 µg of  
282 proteins were used for separation by SDS–PAGE on precast 12 % miniprotean TGX Gels

283 (BioRad) at 205 V, 200 mA for approximately 50 min. Proteins were transferred to  
284 polyvinylidene difluoride (PVDF) membranes (GE Healthcare) and incubated overnight with  
285 anti-Tyrosinase polyclonal antibodies (1:25,000 dilution). Following 1 hour of incubation with  
286 goat anti-rabbit alkaline phosphatase, detection was carried out with NBT/BCIP. The relative  
287 quantification of proteins on SDS-pages was performed using ImageJ (version 1.48f).

288

289

## 290 **Declarations**

291 **Ethics approval and consent to participate:** Not applicable

292 **Consent for publication:** Not applicable

293 **Availability of data and material:** Not applicable

294 **Competing interests:** The authors declare no competing interests

295 **Funding:** This work was supported by grant 12957 from the Dutch Applied Research Council  
296 to DC

297 **Authors' contributions:** BZ performed the experiments with the help of AA, DvD and ER.  
298 DC, BZ and DVD conceived the study. BZ and DC wrote the manuscript with the help of  
299 GPvW. All authors read and approved the final manuscript.

300 **Acknowledgements:** Not applicable

301

302

303

304

305

306 REFERENCES

- 307 1. Barka EA, Vatsa P, Sanchez L, Gavaut-Vaillant N, Jacquard C, Meier-Kolthoff J, Klenk HP,  
308 Clément C, Oudouch Y, van Wezel GP: **Taxonomy, physiology, and natural products of the**  
309 ***Actinobacteria***. *Microbiol Mol Biol Rev* 2016, **80**(1):1-43.
- 310 2. Bérdy J: **Bioactive microbial metabolites**. *J Antibiot (Tokyo)* 2005, **58**(1):1-26.
- 311 3. Vrancken K, Anné J: **Secretory production of recombinant proteins by *Streptomyces***. *Future*  
312 *Microbiol* 2009, **4**(2):181-188.
- 313 4. Zacchetti B, Willemse J, Recter B, van Dissel D, van Wezel GP, Wösten HAB, Claessen D:  
314 **Aggregation of germlings is a major contributing factor towards mycelial heterogeneity of**  
315 ***Streptomyces***. *Sci Rep* 2016, **6**:27045.
- 316 5. Celler K, Piciooreanu C, van Loosdrecht MCM, van Wezel GP: **Structured morphological**  
317 **modeling as a framework for rational strain design of *Streptomyces* species**. *Antonie van*  
318 *Leeuwenhoek* 2012, **102**(3):409-423.
- 319 6. van Dissel D, Claessen D, Roth M, van Wezel GP: **A novel locus for mycelial aggregation**  
320 **forms a gateway to improved *Streptomyces* cell factories**. *Microb Cell Fact* 2015, **14**(1):44.
- 321 7. Liu L, Yang H, Shin HD, Li J, Du G, Chen J: **Recent advances in recombinant protein**  
322 **expression by *Corynebacterium*, *Brevibacterium*, and *Streptomyces*: from transcription and**  
323 **translation regulation to secretion pathway selection**. *Appl Microbiol Biotechnol* 2013,  
324 **97**(22):9597-9608.
- 325 8. Chaplin AK, Petrus MLC, Mangiameli G, Hough MA, Svistunenka DA, Nicholls P, Claessen D,  
326 Vijgenboom E, Worrall JAR: **GlxA is a new structural member of the radical copper oxidase**  
327 **family and is required for glycan deposition at hyphal tips and morphogenesis of**  
328 ***Streptomyces lividans***. *Biochem J* 2015, **469**(3):433-444.
- 329 9. Wardell JN, Stocks SM, Thomas CR, Bushell ME: **Decreasing the hyphal branching rate of**  
330 ***Saccharopolyspora erythraea* NRRL 2338 leads to increased resistance to breakage and**  
331 **increased antibiotic production**. *Biotechnol Bioeng* 2002, **78**(2):141-146.
- 332 10. van Dissel D, Claessen D, van Wezel GP: **Morphogenesis of *Streptomyces* in submerged**  
333 **cultures**. *Adv Appl Microbiol* 2014, **89**:1-45.
- 334 11. Pickup KM, Bushell ME: **Non-fragmenting variants of *Streptomyces* hyphae have enhanced**  
335 **activity of an enzyme (phospho-N-acetylmuramyl pentapeptide translocase) in**  
336 **peptidoglycan biosynthesis**. *J Ferment Bioeng* 1995, **79**(3):247-251.
- 337 12. Nielsen J: **Modelling the morphology of filamentous microorganisms**. *Trends in*  
338 *Biotechnology* 1996, **14**(11):438-443.
- 339 13. Park JK, Chang HN: **Microencapsulation of microbial cells**. *Biotechnol Adv* 2000, **18**(4):303-  
340 319.
- 341 14. Buzas Z, Dallmann K, Szajani B: **Influenc of pH on the growth and ethanol production of free**  
342 **and immobilized *Saccharomyces cerevisiae* cells**. *Biotechnol Bioeng* 1989, **34**(6):882-884.
- 343 15. Russo A, Basaglia M, Tola E, Casella S: **Survival, root colonisation and biocontrol capacities**  
344 **of *Pseudomonas fluorescens* F113 LacZY in dry alginate microbeads**. *J Ind Microbiol*  
345 *Biotechnol* 2001, **27**(6):337-342.
- 346 16. McCabe BK, Kuek C, Gordon GL, Phillips MW: **Production of beta-glucosidase using**  
347 **immobilised *Piromyces* sp. K5X1 and *Orpinomyces* sp. 478P1 in repeat-batch culture**. *J Ind*  
348 *Microbiol Biotechnol* 2003, **30**(4):205-209.
- 349 17. Anisha GS, Prema P: **Cell immobilization technique for the enhanced production of alpha-**  
350 **galactosidase by *Streptomyces griseoalbus***. *Bioresour Technol* 2008, **99**(9):3325-3330.
- 351 18. López-García MT, Rioseras B, Yagüe P, Álvarez JR, Manteca Á: **Cell immobilization of**  
352 ***Streptomyces coelicolor*: effect on differentiation and actinorhodin production**.  
353 *International Microbiology* 2014, **17**(2):75-80.
- 354 19. Najafpour G, Younesi H, Syahidah Ku Ismail K: **Ethanol fermentation in an immobilized cell**  
355 **reactor using *Saccharomyces cerevisiae***. *Bioresour Technol* 2004, **92**(3):251-260.

- 356 20. Cruz-Morales P, Vijgenboom E, Iruegas-Bocardo F, Girard G, Yanez-Guerra LA, Ramos-Aboites  
357 HE, Pernodet JL, Anne J, van Wezel GP, Barona-Gomez F: **The genome sequence of**  
358 ***Streptomyces lividans* 66 reveals a novel tRNA-dependent peptide biosynthetic system**  
359 **within a metal-related genomic island.** *Genome Biol Evol* 2013, **5**(6):1165-1175.
- 360 21. Katz E, Thompson CJ, Hopwood DA: **Cloning and expression of the tyrosinase gene from**  
361 ***Streptomyces antibioticus* in *Streptomyces lividans*.** *J Gen Microbiol* 1983, **129**(9):2703-  
362 2714.
- 363 22. van Veluw GJ, Petrus MLC, Gubbens J, de Graaf R, de Jong IP, van Wezel GP, Wösten HAB,  
364 Claessen D: **Analysis of two distinct mycelial populations in liquid-grown *Streptomyces***  
365 **cultures using a flow cytometry-based proteomics approach.** *Appl Microbiol Biotechnol*  
366 2012, **96**(5):1301-1312.
- 367 23. Large KP, Ison AP, Williams DJ: **The effect of agitation rate on lipid utilisation and clavulanic**  
368 **acid production in *Streptomyces clavuligerus*.** *J Biotechnol* 1998, **63**(2):111-119.
- 369 24. Roubos JA, Krabben P, Luiten RGM, Verbruggen HB, Heijnen JJ: **A quantitative approach to**  
370 **characterizing cell lysis caused by mechanical agitation of *Streptomyces clavuligerus*.**  
371 *Biotechnol Prog* 2001, **17**(2):336-347.
- 372 25. Mehmood N, Olmos E, Marchal P, Goergen JL, Delaunay S: **Relation between pristinamycins**  
373 **production by *Streptomyces pristinaespiralis*, power dissipation and volumetric gas-liquid**  
374 **mass transfer coefficient, kLa.** *Process Biochem* 2010, **45**(11):1779-1786.
- 375 26. Ohta N, Park YS, Yahiro K, Okabe M: **Comparison of neomycin production from**  
376 ***Streptomyces fradiae* cultivation using soybean oil as the sole carbon source in an air-lift**  
377 **bioreactor and a stirred-tank reactor.** *J Ferment Bioeng* 1995, **79**(5):443-448.
- 378 27. Gaserod O, Sannes A, Skjak-Braek G: **Microcapsules of alginate-chitosan. II. A study of**  
379 **capsule stability and permeability.** *Biomaterials* 1999, **20**(8):773-783.
- 380 28. Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE,  
381 Quail MA, Kieser H, Harper D *et al*: **Complete genome sequence of the model actinomycete**  
382 ***Streptomyces coelicolor* A3(2).** *Nature* 2002, **417**(6885):141-147.
- 383 29. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA: **Practical *Streptomyces* genetics.**  
384 Norwich: The John Innes Foundation; 2000.
- 385 30. Bhujbal SV, Paredes-Juarez GA, Niclou SP, de Vos P: **Factors influencing the mechanical**  
386 **stability of alginate beads applicable for immunoisolation of mammalian cells.** *J Mech*  
387 *Behav Biomed Mater* 2014, **37**:196-208.
- 388 31. Willemse J, van Wezel GP: **Imaging of *Streptomyces coelicolor* A3(2) with reduced**  
389 **autofluorescence reveals a novel stage of FtsZ localization.** *PLoS ONE* 2009, **4**(1):e4242.
- 390 32. Kontturi LS, Yliperttula M, Toivanen P, Maatta A, Maatta AM, Urtti A: **A laboratory-scale**  
391 **device for the straightforward production of uniform, small sized cell microcapsules with**  
392 **long-term cell viability.** *J Control Release* 2011, **152**(3):376-381.
- 393 33. Lerch K, Ettinger L: **Purification and characterization of a tyrosinase from *Streptomyces***  
394 ***glaucescens*.** *Eur J Biochem* 1972, **31**(3):427-437.

395

396

397

398

399 **Figure legends:**

400

401 **Figure 1. Morphology of encapsulated streptomycetes in NMMP<sub>mod</sub> medium.**

402 Microscopy images of microcapsules of *Streptomyces coelicolor*, *Streptomyces lividans*,  
403 *Streptomyces venezuelae* and *Streptomyces griseus* grown in NMMP<sub>mod</sub> medium at 48 (top  
404 panel) and 96 h (lower panel). The scale bar corresponds to 200  $\mu$ m.

405

406 **Figure 2. Microencapsulation reduces mycelial damage.** LIVE/DEAD staining of *S.*

407 *lividans* grown in microcapsules (top row), or non-encapsulated in the absence (middle row)  
408 or presence (bottom row) of a metal coil. Mycelium stained with Syto9 (green) represents  
409 viable mycelium, while propidium iodide-stained mycelium (red) is damaged. Whereas  
410 abundant viable mycelium is visible in the encapsulated state at 48 h of growth, the non-  
411 encapsulated mycelium appears highly damaged. Note that the mycelium grown in the  
412 presence of the coil appears already damaged after 36 h. The scale bar represents 200  $\mu$ m  
413 (top panel) or 100  $\mu$ m (middle and bottom panel).

414

415 **Figure 3. Microencapsulation increases tyrosinase activity in the supernatant.** Lines

416 represent the tyrosinase activity present in the supernatant of *S. lividans* pIJ703 grown  
417 encapsulated (green), or non-encapsulated in the absence (red) or presence (blue) of a coil.  
418 The highest activity was observed in the culture broth of the encapsulated mycelium after 48  
419 h of growth.

420

421 **Figure 4. Microencapsulation increases tyrosinase purity in the culture broth. A)** SDS-

422 page showing the protein profiles in the supernatants of cultures of *S. lividans* pIJ703, grown  
423 encapsulated (lanes 2-4), or non-encapsulated in the absence (lanes 5-7) and presence  
424 (lanes 8-10) of a metal coil. All cultures were performed in triplicate. Molecular weight  
425 markers (lane 1) are indicated in kDa. **B)** Western analysis of the abovementioned

426 supernatants using an anti-Tyrosinase antibody. Molecular weight markers are indicated in  
427 kDa.

428

429 **Figure S1: Morphology of encapsulated streptomycetes in YEME medium.** Microscopy  
430 images of microcapsules of *Streptomyces coelicolor*, *Streptomyces lividans*, *Streptomyces*  
431 *venezuelae* and *Streptomyces griseus* grown in YEME medium for 48 (top panel) and 96 h  
432 (lower panel). No scale bar is added since not all pictures are taken using the same  
433 magnification (mainly to allow the visualization of the protruding mycelium). As a reference,  
434 the microcapsules have an average size of 415  $\mu\text{m}$ .

435

436 **Figure S2: Growth and detachment of mycelium from microcapsules containing**  
437 **different streptomycetes.** Overview images of the mycelium of *Streptomyces lividans*,  
438 *Streptomyces griseus* and *Streptomyces venezuelae* grown in  $\text{NMMP}_{\text{mod}}$  medium for 48 (top  
439 panel) and 96 h (lower panel). Note that detached mycelial fragments are evident in the  
440 culture broth of *S. griseus* and *S. venezuelae* at 48 h. After 96 h, detached mycelial  
441 fragments are also observed in *S. lividans*. The scale bar corresponds to 500  $\mu\text{m}$ .

442

443 **Figure S3. Glucose consumption by encapsulated and non-encapsulated mycelium.**  
444 The residual glucose concentrations (in g/L) in  $\text{NMMP}_{\text{mod}}$  medium are shown when  
445 *Streptomyces lividans pJJ703* is grown in micro-capsules (green), or non-encapsulated in the  
446 absence (red) and presence (blue) of a metal coil.

447

448







*S. coelicolor*

*S. lividans*

*S. venezuelae*

*S. griseus*

48 h



96 h







Figure 1




Figure 2




Figure 3




Figure 4